The burgeoning field of radiopharmaceuticals, propelled by the success of treatments like Novartis’s Pluvicto (lutetium Lu 177 vipivotide tetraxetan), is rapidly capturing the attention of the pharmaceutical industry and investors alike. This surge in interest coincides with a significant shift in the cancer treatment paradigm, moving towards targeted combination therapies that offer enhanced efficacy and improved tolerability compared to traditional chemotherapy and radiotherapy regimens. This evolution was a central theme at the American Society of Clinical Oncology (ASCO) 2026 conference, held from May 29 to June 1, where the potential of radioligand therapies (RLTs) was a focal point of numerous discussions and presentations.
The growing intrigue within big pharma is underscored by a series of high-profile, radiopharmaceutical-focused acquisitions and partnerships. Major players such as Eli Lilly, AstraZeneca, and Bristol Myers Squibb (BMS) are actively pursuing stakes in this maturing market. These strategic moves reflect a broader industry trend. According to GlobalData’s Pharmaceutical Intelligence Center, the first quarter of 2026 saw radiopharmaceutical partnerships and licensing agreements reach values 3.5 times higher than in the corresponding period of 2025, indicating a robust increase in deal-making activity. This heightened commercial engagement, particularly evident at ASCO 2026, signifies a maturing segment poised for significant growth.
A decade ago, a single abstract on radiopharmaceuticals at ASCO would have been noteworthy. This year, however, multiple sessions were dedicated to RLTs, a testament to the rapid advancement and increasing clinical relevance of this drug class. The conference provided a platform for key opinion leaders, researchers, and industry executives to delve into the complexities and future directions of radiopharmaceuticals in oncology. Despite the palpable excitement, experts acknowledge that several critical advancements are necessary for radiopharmaceuticals to become a mainstream component of cancer care.
Alpha Emitters: The Next Frontier in Radiotherapy?
A key area of discussion at ASCO 2026 revolved around the potential of high-potency, short-range alpha-emitting therapies. While beta-emitting radiopharmaceuticals, such as Pluvicto and Novartis’s Lutathera (lutetium Lu 177 dotatate), have established a commercial foothold due to their longer-range radioactivity, the industry is increasingly looking towards alpha emitters.
Andy Hsieh, a biotech equity research analyst at William Blair, observed significant interest in this sub-class of radiopharmaceuticals. "The question on the floor was whether high-potency, short-range alpha-emitting therapies have yet to reach their prime," Hsieh noted. He believes the answer is affirmative, but with crucial caveats. "We need to be mindful of the placement of alpha emitters compared to beta therapies," he stressed. "Given the potency and corresponding safety profile of alpha emitters, drug sponsors must carefully consider the benefit-risk ratio for patients when positioning these therapies earlier in the treatment paradigm."
This careful consideration is particularly relevant given the intense energy deposition of alpha particles over very short distances, which can lead to highly localized tumor cell destruction but also raises concerns about potential damage to surrounding healthy tissues. The development of effective delivery mechanisms and precise targeting strategies is therefore paramount for alpha-emitting radiopharmaceuticals.
Jefferies senior equity research analyst, Andrew Tsai, echoed this sentiment, identifying potential in actinium and lead-based alpha-emitting therapies. He highlighted the "quite encouraging" data from Novartis’s Phase I AcTION trial (NCT04597411), which investigated an actinium-based RLT, 225Ac-PSMA-617, in men with metastatic castration-resistant prostate cancer (mCRPC). Presented at ASCO 2026, these early findings suggest a promising efficacy profile for this alpha-targeted approach. Tsai also noted that clinicians expressed enthusiasm for the alpha modality, citing its potential for improved efficacy and a cleaner safety profile. However, he cautioned that based on the data presented thus far, he remains cautiously optimistic.
"I’m encouraged, but alpha and beta therapies each have their pros and cons," Tsai commented. "Novartis has established a smooth supply chain for Pluvicto, and that’s something that needs to be thought about for the alpha class." This pragmatic observation points to the significant logistical and manufacturing challenges that need to be overcome for alpha emitters to achieve widespread clinical adoption. The development of robust and scalable production methods for these highly radioactive isotopes is a critical hurdle.
The Conjugate Debate: Targeting Molecules and Their Implications
Beyond the alpha versus beta discussion, ASCO 2026 also saw extensive debate surrounding the optimal targeting molecules for radiopharmaceuticals. Companies are exploring diverse approaches, developing therapeutics based on antibodies, small molecules, and peptides. Each of these modalities presents unique advantages and disadvantages that influence their efficacy, safety, and clinical applicability.
Andrew Tsai pointed out that at this early stage, the safety profile of small molecule RLTs is gaining attention. "Antibody-based approaches have previously been associated with elevated cases of adverse events (AEs) like cytopenia," he explained. This observation suggests that the immunogenicity and potential for off-target immune responses associated with larger antibody molecules might contribute to increased toxicity.
Andy Hsieh concurred, adding that while small molecules may offer a safety advantage, antibody-based therapies possess superior targeting specificity, which could translate to more potent tumor cell killing. However, he noted that their larger size might hinder their ability to penetrate deep into the tumor microenvironment, potentially limiting their reach to all cancer cells. "Antibody and small molecule-based radiopharmaceuticals have very different half-lives, which result in their own distinct AEs – something that developers would benefit from considering when designing their RLT," Hsieh elaborated. The differing pharmacokinetic profiles of these targeting agents necessitate tailored dosing schedules and patient monitoring strategies.
Looking ahead, Tsai expressed a broad outlook on the competitive landscape. "I don’t think there’s just going to be one or two dominant players in the radiopharmaceutical niche, referring to isotopes and differing modalities," he stated. "Ultimately, I think multiple players can win; that’s my big picture view." This perspective suggests that the field is likely to evolve into a diversified market, with various companies excelling in specific niches based on their technological expertise and therapeutic focus.
On-Target, Off-Tumor Toxicities Remain a Significant Hurdle
Despite the optimistic outlook for radiopharmaceuticals, Hsieh raised significant concerns regarding "on-target, off-tumour" adverse events, particularly in patients with prostate cancer. These issues became acutely apparent during a session dedicated to the Phase I AcTION trial at ASCO 2026. A notable proportion of patients experienced persistent dry mouth, a condition attributed to the accumulation of radiation within the salivary glands. These glands, it was explained, also produce the target antigen, prostate-specific membrane antigen (PSMA), the target of the experimental therapy.
"Dry mouth can be a huge impediment when it comes to quality of life. In the AcTION trial, some patients lost weight because they lost their ability to salivate, which makes it hard to eat; the irreversibility makes it really tough," Hsieh detailed. The long-term and irreversible nature of this side effect presents a considerable challenge, potentially impacting patient adherence and overall treatment outcomes.
This specific adverse event has cast a shadow of reservation among analysts. "We have to be very careful when it comes to frontline, thinking about these longer-term, irreversible impacts on quality of life," Hsieh cautioned. The implications for the widespread adoption of RLTs, especially in earlier lines of therapy, are profound. Developers must prioritize strategies to mitigate such toxicities, potentially through dose optimization, refined targeting mechanisms, or combination approaches that enhance tumor specificity while sparing healthy tissues.
Preliminary data suggest that dry mouth issues might be slightly less prevalent with antibody-based radiopharmaceuticals compared to small molecule alternatives. However, Hsieh emphasized that this trend requires further investigation and validation through larger, more comprehensive clinical trials. Understanding the molecular basis of these on-target, off-tumor effects is crucial for designing the next generation of safer and more effective radiopharmaceuticals.
Accessibility: A Potential Roadblock to Innovation
Beyond the scientific and clinical challenges, Harpreet Singh, former director of oncology at the U.S. Food and Drug Administration and CMO at Precision for Medicine, highlighted a persistent challenge that has long plagued the pharmaceutical industry: "approval doesn’t equal access." For radioligand therapies to truly impact patient care, robust accessibility infrastructure is essential.
Singh outlined several key components for building this infrastructure: a strong and resilient isotope supply chain, secure reimbursement pathways, and the availability of healthcare sites with the necessary capacity and trained workforce to administer these complex treatments. Each of these elements presents significant logistical and financial hurdles.
The potential for fragmented access to approved radiopharmaceuticals could have cascading negative effects on the development of future RLTs. If patients cannot access existing therapies, it complicates the regulatory and technical landscape for emerging players. "Take the classic example of Pluvicto," Singh illustrated. "When the next company wants to develop an asset in prostate cancer, the control arm will likely have to include Pluvicto when running trials in this disease."
Given that prostate cancer trials often enroll over a thousand patients globally, issues related to worldwide access to Pluvicto could force companies to modify their trial designs. This might involve adopting an investigator’s choice comparator arm, where Pluvicto is an option but not a mandatory component. Singh described such a scenario as "less than ideal for the FDA," which seeks trial data that accurately reflects the U.S. population.
"It’s not the FDA’s purview to grant access, and if people don’t have access to the best available option, it can jeopardize the regulatory and technical strategy for emerging assets," Singh explained. This could, in turn, impact patient access to next-generation transformative therapies if these new treatments cannot be adequately studied against FDA-approved comparators due to accessibility limitations.
Andrew Tsai further emphasized the critical need for companies to demonstrate scalability in production, transitioning from clinical development to commercial manufacturing. This challenge is particularly acute for RLTs that rely on short-half-life isotopes like lead. These isotopes necessitate production facilities located in close proximity to hospitals to ensure the efficacy and timely administration of the therapy. "In some cases, it’s almost more of an idea than something established," Tsai concluded, underscoring the significant practical considerations that lie ahead for the widespread implementation of radiopharmaceuticals. The journey from promising clinical data to widespread patient benefit is a complex one, requiring innovation not only in drug development but also in manufacturing, logistics, and healthcare system integration.
